President's Commission on Combating Drug Addiction and the Opioid Crisis

President's Commission on Combating Drug Addiction and the Opioid Crisis
Name	President's Commission on Combating Drug Addiction and the Opioid Crisis
Formed	2017
Dissolved	2018
Jurisdiction	United States
Chief1 name	Chris Christie
Chief1 position	Chair
Parent agency	Executive Office of the President

President's Commission on Combating Drug Addiction and the Opioid Crisis was a presidential commission established in 2017 to address the opioid epidemic in the United States. The commission produced a high-profile report in 2017 that influenced federal, state, and local policy debates. It operated at the intersection of health policy, law enforcement, and legislative action during the Trump administration.

Background and Establishment

The commission was created by executive action in response to rising overdose deaths linked to prescription opioids, heroin, and fentanyl, situating its work amid public health crises acknowledged by the Centers for Disease Control and Prevention, National Institutes of Health, and the Substance Abuse and Mental Health Services Administration. Its formation followed policy attention from the 2016 United States presidential election, legislative activity in the 115th United States Congress, and advocacy from groups such as the American Medical Association and Mothers Against Drunk Driving. The commission's launch referenced prior federal efforts including the Office of National Drug Control Policy, the Comprehensive Addiction and Recovery Act of 2016, and initiatives by state governors like Scott Walker and Andrew Cuomo.

Membership and Leadership

The commission was chaired by former Governor Chris Christie and included health officials, law enforcement leaders, and private-sector executives. Prominent members and advisors included officials with ties to the Department of Health and Human Services, the Department of Justice, and the Department of Veterans Affairs, as well as figures from academia such as researchers connected to Johns Hopkins University and Harvard Medical School. Law enforcement representation echoed leadership from municipal and federal agencies including the Federal Bureau of Investigation and state prosecutors. The commission convened hearings with witnesses drawn from advocacy organizations like Smart Approaches to Marijuana, treatment providers such as Hazelden Betty Ford Foundation, and families affected through networks like Shatterproof.

Mandate and Objectives

Charged by the Executive Office of the President, the commission's mandate covered prevention, treatment, recovery, and law enforcement responses to opioid misuse. It aimed to recommend interventions compatible with statutes like the Controlled Substances Act and to coordinate with agencies including the Food and Drug Administration and the Drug Enforcement Administration. Objectives emphasized expanding access to medication-assisted treatment endorsed by researchers at institutions such as Yale School of Medicine and Columbia University Medical Center, enhancing prescription monitoring programs modeled after state-level efforts in Rhode Island and Ohio, and disrupting supply chains linked to international trafficking through cooperation with entities like Department of Homeland Security.

Key Findings and Recommendations

The commission's report concluded that the opioid crisis represented a national public health emergency and proposed aggressive measures. Recommendations included declaring a formal national emergency, expanding inpatient and outpatient treatment capacity through federal funding similar to provisions in the Ryan White CARE Act model, increasing distribution of naloxone championed by public health advocates at Mount Sinai Health System, and tightening prescribing practices via guidelines reminiscent of the Centers for Disease Control and Prevention opioid prescribing guideline. It urged law enforcement strategies to target illicit fentanyl networks tied to transnational criminal organizations noted by the United Nations Office on Drugs and Crime and to bolster interdiction with support from the U.S. Customs and Border Protection. The report also suggested liability and civil remedies discussions involving stakeholders such as state attorneys general, including figures like Eric Schneiderman and Jeff Sessions-era Department of Justice perspectives.

Implementation and Impact

Following publication, several elements influenced policy debates in the 115th United States Congress and state legislatures, shaping appropriations for agencies such as the Health Resources and Services Administration and pilot programs in states like Kentucky and Ohio. Presidential actions and administrative priorities linked to the commission intersected with regulatory changes at the Food and Drug Administration and expanded grants through the Substance Abuse and Mental Health Services Administration. The commission's emphasis on treatment access contributed to increased Medicaid coverage decisions in several states and to initiatives by private insurers guided by recommendations from health policy researchers at RAND Corporation and Kaiser Family Foundation.

Criticism and Controversies

Critics questioned the commission's emphasis on criminal justice responses and its ties to political figures, raising concerns from public health scholars at Columbia University Mailman School of Public Health and civil liberties groups such as the American Civil Liberties Union. Investigative reporting in outlets like The New York Times and The Washington Post scrutinized internal deliberations and potential industry influences involving pharmaceutical manufacturers previously subject to litigation by state attorneys general including Maura Healey and Xavier Becerra. Advocates for harm reduction from organizations like Harm Reduction Coalition argued the recommendations underweighted syringe service programs supported by Centers for Disease Control and Prevention guidance. Legal scholars debated the wisdom of recommending a national emergency relative to frameworks in the Robert T. Stafford Disaster Relief and Emergency Assistance Act.

Category:United States public health